Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Amos Katz, Jonathan Myers et al.|The Lancet|2020Cited by 1.2k
Efficacy and Safety of Acoramidis in Transthyretin Amyloid CardiomyopathyJulian D. Gillmore, Jonathan C. Fox, Daniel P. Judge et al.|New England Journal of Medicine|2024Cited by 453
Aficamten for Symptomatic Obstructive Hypertrophic CardiomyopathyMartin S. Maron, Theodore P. Abraham, Ahmad Masri et al.|New England Journal of Medicine|2024Cited by 277
Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic CardiomyopathySara Saberi, Daniel Jacoby, Nuno Cardim et al.|Circulation|2020Cited by 234
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic CardiomyopathyMartin S. Maron, Theodore P. Abraham, Ahmad Masri et al.|Journal of the American College of Cardiology|2023Cited by 192